Moleculin Biotech, Inc. (MBRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.1800 |
| Open | 1.1400 |
| Bid | 1.1300 x 800 |
| Ask | 1.1900 x 1100 |
| Day's Range | 1.0710 - 1.2199 |
| 52 Week Range | 1.0200 - 3.0800 |
| Volume | |
| Avg. Volume | 97,534 |
| Market Cap | 32.898M |
| Beta (5Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6410 |
| Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MBRX
Related Research
- Moleculin Biotech, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Skyworks soars, Big Biopharma builds immunity to headwinds, and Baidu and the cloud; and Harmonic Drive Systems, Elekta, and Nabtesco.RatingFair ValueEconomic Moat4 months agoMorningstar
- PR Newswire
Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder, President, CEO and Chairman, and Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin will participate in the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event on Wednesday, September 28, 2022 at 11:00 AM ET.
- PR Newswire
Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will virtually present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, NY September 8-10, 2022.
- PR Newswire
Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
